Non-alcoholic fatty liver disease screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (14 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for NAFLD. | There is insufficient evidence to recommend routine screening for NAFLD in general population. However, screening is recommended in high-risk population groups([[obesity]], [[insulin resistance]] and patients with [[metabolic syndrome]]) as more than 50 million Americans have been estimated to have metabolic syndrome and about 80% of them have NAFD. | ||
==Screening== | ==Screening== | ||
* There is insufficient evidence to recommend routine screening for NAFLD. | * There is insufficient evidence to recommend routine screening for NAFLD in general population.<ref name="pmid28544608">{{cite journal| author=Koot BGP, Nobili V| title=Screening for non-alcoholic fatty liver disease in children: do guidelines provide enough guidance? | journal=Obes Rev | year= 2017 | volume= 18 | issue= 9 | pages= 1050-1060 | pmid=28544608 | doi=10.1111/obr.12556 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28544608 }} </ref><ref name="pmid28213828">{{cite journal| author=Kummer S, Klee D, Kircheis G, Friedt M, Schaper J, Häussinger D et al.| title=Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis. | journal=Eur J Pediatr | year= 2017 | volume= 176 | issue= 4 | pages= 529-536 | pmid=28213828 | doi=10.1007/s00431-017-2876-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28213828 }} </ref><ref name="pmid27605111">{{cite journal| author=Glen J, Floros L, Day C, Pryke R, Guideline Development Group| title=Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. | journal=BMJ | year= 2016 | volume= 354 | issue= | pages= i4428 | pmid=27605111 | doi=10.1136/bmj.i4428 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27605111 }} </ref> | ||
* However, American Gastroenterological Association Technical Review recommends screening for non-alcoholic fatty liver disease in population at high risk such as [[obesity]], [[insulin resistance]], and [[metabolic syndrome]]. | |||
* Screening is however complicated by the lack of accurate, noninvasive diagnostic tools for NAFLD and the lack of clear treatment that can be proposed to the patient. | |||
{{ | |||
{{ | |||
{{ | |||
However, the AGA recommend screening<ref name="pmid37542503">{{cite journal| author=Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ| title=AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. | journal=Gastroenterology | year= 2023 | volume= | issue= | pages= | pmid=37542503 | doi=10.1053/j.gastro.2023.06.013 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37542503 }} </ref>. | |||
Workflows to promote screening may increase treatment<ref name="pmid37549979">{{cite journal| author=Zhang X, Yip TC, Wong GL, Leow WX, Liang LY, Lim LL | display-authors=etal| title=Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial. | journal=Gut | year= 2023 | volume= | issue= | pages= | pmid=37549979 | doi=10.1136/gutjnl-2023-330269 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37549979 }} </ref>. | |||
== Screening modalities == | |||
* Serum tests of liver function | |||
* | |||
==References== | ==References== | ||
Latest revision as of 01:49, 25 August 2023
|
Non-Alcoholic Fatty Liver Disease Microchapters |
|
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case studies |
|
Non-alcoholic fatty liver disease screening On the Web |
|
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease screening |
|
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
|
Risk calculators and risk factors for Non-alcoholic fatty liver disease screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
There is insufficient evidence to recommend routine screening for NAFLD in general population. However, screening is recommended in high-risk population groups(obesity, insulin resistance and patients with metabolic syndrome) as more than 50 million Americans have been estimated to have metabolic syndrome and about 80% of them have NAFD.
Screening
- There is insufficient evidence to recommend routine screening for NAFLD in general population.[1][2][3]
- However, American Gastroenterological Association Technical Review recommends screening for non-alcoholic fatty liver disease in population at high risk such as obesity, insulin resistance, and metabolic syndrome.
- Screening is however complicated by the lack of accurate, noninvasive diagnostic tools for NAFLD and the lack of clear treatment that can be proposed to the patient.
However, the AGA recommend screening[4].
Workflows to promote screening may increase treatment[5].
Screening modalities
- Serum tests of liver function
References
- ↑ Koot BGP, Nobili V (2017). "Screening for non-alcoholic fatty liver disease in children: do guidelines provide enough guidance?". Obes Rev. 18 (9): 1050–1060. doi:10.1111/obr.12556. PMID 28544608.
- ↑ Kummer S, Klee D, Kircheis G, Friedt M, Schaper J, Häussinger D; et al. (2017). "Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis". Eur J Pediatr. 176 (4): 529–536. doi:10.1007/s00431-017-2876-1. PMID 28213828.
- ↑ Glen J, Floros L, Day C, Pryke R, Guideline Development Group (2016). "Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance". BMJ. 354: i4428. doi:10.1136/bmj.i4428. PMID 27605111.
- ↑ Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ (2023). "AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review". Gastroenterology. doi:10.1053/j.gastro.2023.06.013. PMID 37542503 Check
|pmid=value (help). - ↑ Zhang X, Yip TC, Wong GL, Leow WX, Liang LY, Lim LL; et al. (2023). "Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial". Gut. doi:10.1136/gutjnl-2023-330269. PMID 37549979 Check
|pmid=value (help).